How we manage medication-related osteonecrosis of the jaw.
Bone-modifying agents
Dental oncology
Medication-related osteonecrosis of the jaw
Multidisciplinary patient care
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
02 Aug 2024
02 Aug 2024
Historique:
received:
08
05
2023
accepted:
30
05
2024
medline:
3
8
2024
pubmed:
3
8
2024
entrez:
2
8
2024
Statut:
epublish
Résumé
Bone-modifying agents (BMAs) are integral to managing patients with advanced cancer. They improve quality of survival by reducing skeletal-related events, treating hypercalcaemia and chemotherapy-induced bone loss (Coleman in Clin Cancer Res 12: 6243s-6249s, 2006), (Coleman in Ann Oncol 31: 1650-1663, 2020). Two decades ago, medication-related osteonecrosis of the jaw (MRONJ) was first reported following BMA therapy (Marx in J Oral Maxillofac Surg 61: 1115-1117, 2003). The risk of MRONJ extends over a decade following BMA treatment with bisphosphonates, complicating dental care such as extractions. In addition, MRONJ has been reported following additional therapies such as antiangiogenic agents, cytotoxic agents, immunotherapy, and targeted agents. The use of BMAs in the curative and adjuvant cancer setting is increasing, consequently the implication of MRONJ is growing. Over the past 20 years, the literature has consolidated major risk factors for MRONJ, the pathophysiology and management strategies for MRONJ. Our review aims to document the development of MRONJ preventative and management strategies in cancer patients receiving a BMA. The authors advocate the incorporation of dental oncology strategies into contemporary cancer care, to optimise long-term quality of survival after cancer treatment.
Identifiants
pubmed: 39095845
doi: 10.1186/s40001-024-01912-6
pii: 10.1186/s40001-024-01912-6
doi:
Substances chimiques
Bone Density Conservation Agents
0
Antineoplastic Agents
0
Diphosphonates
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
402Informations de copyright
© 2024. The Author(s).
Références
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s-s6249.
pubmed: 17062708
doi: 10.1158/1078-0432.CCR-06-0931
Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO Clinical Practice Guidelines†. Ann Oncol. 2020;31(12):1650–63.
pubmed: 32801018
doi: 10.1016/j.annonc.2020.07.019
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–7.
pubmed: 12966493
doi: 10.1016/S0278-2391(03)00720-1
Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American association of oral and maxillofacial surgeons’ position paper on medication-related osteonecrosis of the Jaws-2022 update. J Oral Maxillofac Surg. 2022;80(5):920–43.
pubmed: 35300956
doi: 10.1016/j.joms.2022.02.008
von Moos R, Costa L, Gonzalez-Suarez E, Terpos E, Niepel D, Body JJ. Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody. Cancer Treat Rev. 2019;76:57–67.
doi: 10.1016/j.ctrv.2019.05.003
D’Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: pathogenesis and therapeutic options: Up-date on bone metastasis management. J Bone Oncol. 2019;1(15):100205.
doi: 10.1016/j.jbo.2018.10.004
World Health Assembly 66. Follow-up to the Political Declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. Report No.: WHA66.10. 2013. https://apps.who.int/iris/handle/10665/150161 . Accessed 12 Dec 2022.
Agrasuta V, Thumbuntu T, Karawekpanyawong R, Panichkriangkrai W, Viriyathorn S, Reeponmaha T, et al. Progressive realisation of universal access to oral health services: what evidence is needed? BMJ Glob Health. 2021;6(7):e006556.
pubmed: 34257139
pmcid: 8278897
doi: 10.1136/bmjgh-2021-006556
Marcianò A, Rubino E, Peditto M, Mauceri R, Oteri G. Oral surgical management of bone and soft tissues in MRONJ treatment: a decisional tree. Life (Basel). 2020;10(7):99.
pubmed: 32610675
Moreno-Rabié C, Lapauw L, Gaêta-Araujo H, Ferreira-Leite A, Coucke W, van den Wyngaert T, et al. Radiographic predictors for MRONJ in oncologic patients undergoing tooth extraction. Sci Rep. 2022;4(12):11280.
doi: 10.1038/s41598-022-15254-y
Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010;136(8):1117–24.
pubmed: 20508948
doi: 10.1007/s00432-010-0907-7
McMahon RE, Bouquot JE, Glueck CJ, Griep JA, Adams WR, Spolnik KJ, et al. Staging bisphosphonate-related osteonecrosis of the jaw should include early stages of disease. J Oral Maxillofac Surg. 2007;65(9):1899–900.
pubmed: 17719423
doi: 10.1016/j.joms.2007.04.021
Bedogni A, Fusco V, Agrillo A, Campisi G. Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Dis. 2012;18(6):621–3.
pubmed: 22353421
pmcid: 3443365
doi: 10.1111/j.1601-0825.2012.01903.x
Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017;35(1):6–19.
doi: 10.1007/s00774-016-0810-7
Caminha RDG, Alcantara PL, Carvalho CG, Reia VCB, Capelozza ALA, da Santos PSS. The impact of medication-related osteonecrosis of the jaws on the quality of life in cancer patients. J Clin Exp Dent. 2020;12(8):e725-9.
pubmed: 32913568
pmcid: 7474943
doi: 10.4317/jced.56307
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–56.
pubmed: 25234529
doi: 10.1016/j.joms.2014.04.031
AlRowis R, Aldawood A, AlOtaibi M, Alnasser E, AlSaif I, Aljaber A, et al. Medication-Related Osteonecrosis of the Jaw (MRONJ): a review of pathophysiology, risk factors, preventive measures and treatment strategies. Saudi Dent J. 2022;34(3):202–10.
pubmed: 35935720
pmcid: 9346931
doi: 10.1016/j.sdentj.2022.01.003
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(1):60–72.
pubmed: 31806543
doi: 10.1016/S1470-2045(19)30687-4
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws–2009 update. J Oral Maxillofac Surg. 2009;67(5 Suppl):2–12.
pubmed: 19371809
Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, et al. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). J Bone Oncol. 2018;13:123–35.
pubmed: 30591866
pmcid: 6303395
doi: 10.1016/j.jbo.2018.09.008
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679–91.
pubmed: 19213681
doi: 10.1056/NEJMoa0806285
Kizub DA, Miao J, Schubert MM, Paterson AHG, Clemons M, Dees EC, et al. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). Support Care Cancer. 2021;29(5):2509–17.
pubmed: 32929540
doi: 10.1007/s00520-020-05748-8
Paterson AHG, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012;13(7):734–42.
pubmed: 22704583
pmcid: 4970583
doi: 10.1016/S1470-2045(12)70226-7
Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist. 2013;18(4):353–61.
pubmed: 23404816
pmcid: 3639520
doi: 10.1634/theoncologist.2012-0261
Vidula N, Greenberg S, Petrillo L, Hwang J, Melisko M, Goga A, et al. Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. NPJ Breast Cancer. 2021;7(1):113.
pubmed: 34489453
pmcid: 8421499
doi: 10.1038/s41523-021-00323-8
von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol. 2013;31(28):3531–9.
doi: 10.1200/JCO.2012.47.2167
Fusco V, Alessio M, Guglielmini PF, Vincenti M, Fasciolo A, Rossi M. Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4/6 inhibitors? A Word of Cautiousness. Comment on Marcianò et al. medication-related osteonecrosis of the jaws and CDK4/6 Inhibitors: a recent association. Int J Environ Res Public Health. 2020; 17: 9509. Int J Environ Res Public Health. 2021; 18(19): 10143.
Hallmer F, Bjarnadottir O, Götrick B, Malmström P, Andersson G. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;130(3):252–7.
pubmed: 32536575
doi: 10.1016/j.oooo.2020.04.808
Petrovic M, Jelovac DB, Antic S, Antunovic M, Lukic N, Sabani M, et al. Medication-related osteonecrosis of the jaws: two center retrospective cohort studies. Biomed Res Int. 2019;18(2019):8345309.
Jung S, Kim J, Park JH, Kim KY, Kim HJ, Park W. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients. Sci Rep. 2022;12(1):8641.
pubmed: 35606457
pmcid: 9126865
doi: 10.1038/s41598-022-11615-9
Milosavljević M, Jovanović M, Folić M, Živić M, Zdravković D, Veličković S, et al. Possible association of methotrexate use with osteonecrosis of the jaw: systematic review. J Stomatol Oral Maxillofac Surg. 2022;123(5):e458–63.
pubmed: 35306206
doi: 10.1016/j.jormas.2022.03.012
Owosho AA, Liang STY, Sax AZ, Wu K, Yom SK, Huryn JM, et al. Medication-related osteonecrosis of the jaw (MRONJ): an update on the Memorial Sloan Kettering Cancer Center (MSKCC) experience and the role of Pre-medication Dental Evaluation in the prevention of MRONJ. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(5):440–5.
pubmed: 29580668
pmcid: 7518027
doi: 10.1016/j.oooo.2018.02.003
Decaux J, Magremanne M. Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab. J Stomatol Oral Maxillofac Surg. 2020;121(6):740–2.
pubmed: 32413422
doi: 10.1016/j.jormas.2020.05.001
Vallina C, Ramírez L, Torres J, Casañas E, Hernández G, López-Pintor RM. Osteonecrosis of the jaws produced by sunitinib: a systematic review. Med Oral Patol Oral Cir Bucal. 2019;24(3):e326–38.
pubmed: 31011143
pmcid: 6530944
doi: 10.4317/medoral.22858
Yamamoto D, Tsubota Y, Utsunomiya T, Sueoka N, Ueda A, Endo K, et al. Osteonecrosis of the jaw associated with everolimus: a case report. Mol Clin Oncol. 2017;6(2):255–7.
pubmed: 28357105
doi: 10.3892/mco.2016.1100
Granate-Marques A, Polis-Yanes C, Seminario-Amez M, Jané-Salas E, López-López J. Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: systematic review. Med Oral Patol Oral Cir Bucal. 2019;24(2):e195-203.
pubmed: 30818312
pmcid: 6441601
Bolette A, Lecloux G, Rompen E, Albert A, Kerckhofs G, Lambert F. Influence of induced infection in medication-related osteonecrosis of the jaw development after tooth extraction: a study in rats. J Craniomaxillofac Surg. 2019;47(2):349–56.
pubmed: 30595476
doi: 10.1016/j.jcms.2018.08.011
Otto S, Tröltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg. 2015;43(6):847–54.
pubmed: 25958767
doi: 10.1016/j.jcms.2015.03.039
Cavalcante RC, Tomasetti G. Pentoxifylline and tocopherol protocol to treat medication-related osteonecrosis of the jaw: a systematic literature review. J Craniomaxillofac Surg. 2020;48(11):1080–6.
pubmed: 32998853
doi: 10.1016/j.jcms.2020.09.008
Patel V, Gadiwalla Y, Sassoon I, Sproat C, Kwok J, McGurk M. Prophylactic use of pentoxifylline and tocopherol in patients who require dental extractions after radiotherapy for cancer of the head and neck. Br J Oral Maxillofac Surg. 2016;54(5):547–50.
pubmed: 26975577
doi: 10.1016/j.bjoms.2016.02.024
Hadaya D, Soundia A, Freymiller E, Grogan T, Elashoff D, Tetradis S, et al. Nonsurgical management of medication-related osteonecrosis of the jaws using local wound care. J Oral Maxillofac Surg. 2018;76(11):2332–9.
pubmed: 29932939
pmcid: 6265090
doi: 10.1016/j.joms.2018.05.025
Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication-related osteonecrosis of the jaw. J Dent Res. 2015;94(4):534–9.
pubmed: 25710950
doi: 10.1177/0022034515572021
Soutome S, Otsuru M, Hayashida S, Murata M, Yanamoto S, Sawada S, et al. Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients. Sci Rep. 2021;26(11):17226.
doi: 10.1038/s41598-021-96480-8
Otto S, Aljohani S, Fliefel R, Ecke S, Ristow O, Burian E, et al. Infection as an important factor in medication-related osteonecrosis of the jaw (MRONJ). Medicina (Kaunas). 2021;57(5):463.
pubmed: 34065104
doi: 10.3390/medicina57050463
Aghaloo TL, Cheong S, Bezouglaia O, Kostenuik P, Atti E, Dry SM, et al. RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease. J Bone Miner Res. 2014;29(4):843–54.
pubmed: 24115073
doi: 10.1002/jbmr.2097
Marx RE. Drug-induced osteonecrosis of the jaws: how to diagnose, prevent, and treat it. Incorporated: Quintessence Publishing Company; 2021. p. 93.
Sacco R, Woolley J, Yates J, Calasans-Maia MD, Akintola O, Patel V. The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: a systematic review. J Res Med Sci: Off J Isfahan Univ Med Sci. 2021; 26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240545/ .
Kabilova TO, Kovtonyuk LV, Zonov EV, Ryabchikova EI, Popova NA, Nikolin VP, et al. Immunotherapy of hepatocellular carcinoma with small double-stranded RNA. BMC Cancer. 2014;14(1):338.
pubmed: 24886485
pmcid: 4038722
doi: 10.1186/1471-2407-14-338
McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis. 2018;24(4):527–36.
pubmed: 28656643
doi: 10.1111/odi.12708
Varoni EM, Lombardi N, Villa G, Pispero A, Sardella A, Lodi G. Conservative management of Medication-Related Osteonecrosis of the Jaws (MRONJ): a retrospective cohort study. Antibiotics (Basel). 2021;10(2):195.
pubmed: 33671429
doi: 10.3390/antibiotics10020195
Mauceri R, Coniglio R, Abbinante A, Carcieri P, Tomassi D, Panzarella V, et al. The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists. Support Care Cancer. 2022;30(8):6429–40.
pubmed: 35292850
pmcid: 9213300
doi: 10.1007/s00520-022-06940-8
Sim IW, Borromeo GL, Tsao C, Hardiman R, Hofman MS, Papatziamos Hjelle C, et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. J Clin Oncol. 2020;38(26):2971–80.
pubmed: 32614699
doi: 10.1200/JCO.19.02192
Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. JBMR Plus. 2022;6(9):e10665.
pubmed: 36111201
pmcid: 9465003
doi: 10.1002/jbm4.10665
Shim GJ, Ohe JY, Yoon YJ, Kwon YD, Kim DY. Current trends in adjuvant therapies for medication-related osteonecrosis of the jaw. Appl Sci. 2022;12(8):4035.
doi: 10.3390/app12084035
Morishita K, Yamada SI, Kawakita A, Hashidume M, Tachibana A, Takeuchi N, et al. Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): a multicenter retrospective analysis in Japan. J Orthop Sci. 2020;25(6):1079–83.
pubmed: 32111549
doi: 10.1016/j.jos.2020.01.012
Ferreira LDS, Abreu LG, Calderipe CB, Martins MD, Schuch LF, Vasconcelos ACU. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? a systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022;134(3):e229.
doi: 10.1016/j.oooo.2022.01.731
RAPTOR: Randomised Controlled Trial of PENTOCLO in Mandibular Osteoradionecrosis - NIHR Funding and Awards. https://fundingawards.nihr.ac.uk/award/NIHR131050 .
Heifetz-Li JJ, Abdelsamie S, Campbell CB, Roth S, Fielding AF, Mulligan JP. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;128(5):491-497.e2.
pubmed: 31488389
doi: 10.1016/j.oooo.2019.08.004
Russmueller G, Seemann R, Weiss K, Stadler V, Speiss M, Perisanidis C, et al. The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. Sci Rep. 2016;6:31604.
pubmed: 27530150
pmcid: 4987681
doi: 10.1038/srep31604
Moretti F, Pelliccioni GA, Montebugnoli L, Marchetti C. A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(6):777–82.
pubmed: 22000426
doi: 10.1016/j.tripleo.2011.07.004
Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23.
pubmed: 25414052
doi: 10.1002/jbmr.2405
Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg. 2007;65(7):1321–7.
pubmed: 17577496
doi: 10.1016/j.joms.2007.03.019
Agrillo A, Fabio F, Ramieri V, Riccardi E, Quarato D, Rinna C, et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy. Eur Rev Med Pharmacol Sci. 2012;1(16):1741–8.
Min SH, Kang NE, Song SI, Lee JK. Regenerative effect of recombinant human bone morphogenetic protein-2/absorbable collagen sponge (rhBMP-2/ACS) after sequestrectomy of medication-related osteonecrosis of the jaw (MRONJ). J Korean Assoc Oral Maxillofac Surg. 2020;46(3):191–6.
pubmed: 32606280
pmcid: 7338633
doi: 10.5125/jkaoms.2020.46.3.191
Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22(4):233–41.
pubmed: 15621726
doi: 10.1080/08977190412331279890
Robijns J, Nair RG, Lodewijckx J, Arany P, Barasch A, Bjordal JM, et al. Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022. Front Oncol. 2022. https://doi.org/10.3389/fonc.2022.927685 .
doi: 10.3389/fonc.2022.927685
pubmed: 36110957
pmcid: 9468822
Nica D, Rivis M, Roi C, Todea C, Duma VF, Sinescu C. Complementarity of photo-biomodulation, surgical treatment, and antibiotherapy for medication-related osteonecrosis of the jaws (MRONJ). Medicina (Kaunas). 2021;5(57):145.
doi: 10.3390/medicina57020145
Zheng Y, Dong X, Chen S, He Y, An J, Liu M, et al. Low-level laser therapy prevents medication-related osteonecrosis of the jaw-like lesions via IL-1RA-mediated primary gingival wound healing. BMC Oral Health. 2023;23(1):14.
pubmed: 36627695
pmcid: 9832759
doi: 10.1186/s12903-022-02678-1
Epstein JB, Arany PR, Yost SE, Yuan Y. Medication-related osteonecrosis of the jaw: successful medical management of complex maxillary alveolus with sinus involvement. Case Rep Oncol. 2023;16(1):412–28.
pmcid: 10294216
doi: 10.1159/000529502
Maines E, Monti E, Doro F, Morandi G, Cavarzere P, Antoniazzi F. Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw. J Bone Miner Metab. 2012;30(4):434–8.
pubmed: 22065238
doi: 10.1007/s00774-011-0331-3
Wutzl A, Pohl S, Sulzbacher I, Seemann R, Lauer G, Ewers R, Drach J, Klug C. Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws. Head Neck. 2012;34:194–200.
pubmed: 21400630
doi: 10.1002/hed.21708
Schubert M, Klatte I, Linek W, Müller B, Döring K, Eckelt U, et al. The Saxon bisphosphonate register - therapy and prevention of bisphosphonate-related osteonecrosis of the jaws. Oral Oncol. 2012;48(4):349–54.
pubmed: 22130456
doi: 10.1016/j.oraloncology.2011.11.004
Voss PJ, Joshi Oshero J, Kovalova-Müller A, Veigel Merino EA, Sauerbier S, Al-Jamali J, et al. Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. J Craniomaxillofac Surg. 2012;40(8):719–25.
pubmed: 22336489
doi: 10.1016/j.jcms.2012.01.005
Pautke C, Bauer F, Otto S, Tischer T, Steiner T, Weitz J, et al. Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. J Oral Maxillofac Surg. 2010;1(69):84–91.
Marcianò A, Guzzo GM, Peditto M, Picone A, Oteri G. Medication-related osteonecrosis of the jaws and CDK4/6 inhibitors: a recent association. Int J Environ Res Public Health. 2020;17(24):9509.
pubmed: 33353034
pmcid: 7767118
doi: 10.3390/ijerph17249509
Sacco R, Sacco N, Hamid U, Ali SH, Singh M, Blythe JSJ. Microsurgical reconstruction of the jaws using vascularised free flap technique in patients with medication-related osteonecrosis: a systematic review. Biomed Res Int. 2018;2018:9858921.
pubmed: 29977926
pmcid: 6011121
doi: 10.1155/2018/9858921
Qaisi M, Montague L. Bone margin analysis for osteonecrosis and osteomyelitis of the jaws. Oral Maxillofac Surg Clin North Am. 2017;29(3):301–13.
pubmed: 28709531
doi: 10.1016/j.coms.2017.03.007
Lopes RN, Rabelo GD, Rocha AC, Carvalho PAG, Alves FA. Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: six-year experience of a single institution. J Oral Maxillofac Surg. 2015;73(7):1288–95.
pubmed: 25871903
doi: 10.1016/j.joms.2015.01.008
Raber-Durlacher JE, Elad S, Barasch A. Oral mucositis. Oral Oncol. 2010;46(6):452–6.
pubmed: 20403721
doi: 10.1016/j.oraloncology.2010.03.012
Migliorati CA, Epstein JB, Abt E, Berenson JR. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol. 2011;7(1):34–42.
pubmed: 21079615
doi: 10.1038/nrendo.2010.195
Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136(12):1658–68.
pubmed: 16383047
doi: 10.14219/jada.archive.2005.0108
Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009;20(1):137–45.
pubmed: 18647964
doi: 10.1093/annonc/mdn526
Campisi G, Russo L, Agrillo A, Vescovi P, Fusco V, Bedogni A. BRONJ expert panel recommendation of the Italian Societies for Maxillofacial Surgery (SICMF) and Oral Pathology and Medicine (SIPMO) on Bisphosphonate-Related Osteonecrosis of the Jaws: risk assessment, preventive strategies and dental management. It J Maxillofac Surg. 2011;1(22):103–24.
Vandone AM, Donadio M, Mozzati M, Ardine M, Polimeni MA, Beatrice S, et al. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol. 2012;23(1):193–200.
pubmed: 21427065
doi: 10.1093/annonc/mdr039
Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O, Peter JU. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2022;7(7):CD012432.
pubmed: 35866376
Bedogni A, Mauceri R, Fusco V, Bertoldo F, Bettini G, Fede OD, et al. Italian Position Paper (SIPMO-SICMF) on Medication-Related Osteonecrosis of the Jaw (MRONJ). Qeios. 2023 Mar 27. https://www.qeios.com/read/PBUJ6Z .
Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O, Peter JU. Interventions for managing medication‐related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2022; 2022(7). https://www.readcube.com/articles/10.1002%2F14651858.cd012432.pub3 .
Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. JCO. 2019;37(25):2270–90.
doi: 10.1200/JCO.19.01186
Cabras M, Gambino A, Broccoletti R, Sciascia S, Arduino PG. Lack of evidence in reducing risk of MRONJ after teeth extractions with systemic antibiotics. J Oral Sci. 2021;63(3):217–26.
pubmed: 34193777
doi: 10.2334/josnusd.21-0016
Campisi G, Mauceri R, Bertoldo F, Bettini G, Biasotto M, Colella G, et al. Medication-Related Osteonecrosis of Jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020. Int J Environ Res Public Health. 2020;17(16):5998.
pubmed: 32824826
pmcid: 7460511
doi: 10.3390/ijerph17165998
Bramati A, Girelli S, Farina G, Dazzani MC, Torri V, Moretti A, et al. Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab. 2015;33(1):119–24.
pubmed: 24553860
doi: 10.1007/s00774-014-0566-x
Trosman JR, Carlos RC, Simon MA, Madden DL, Gradishar WJ, Benson AB, et al. Care for a patient with cancer as a project: management of complex task interdependence in cancer care delivery. J Oncol Pract. 2016;12(11):1101–13.
pubmed: 27577619
pmcid: 5455414
doi: 10.1200/JOP.2016.013573
Bledsaw K, Prudowsky ZD, Yang E, Harriehausen CX, Robins J, DeJean J, et al. A novel oncodental collaborative team: integrating expertise for central line-associated bloodstream infection prevention in pediatric oncology patients. JCO Oncol Pract. 2023;19(1):e25-32.
pubmed: 36137251
doi: 10.1200/OP.22.00302
Mücke T, Deppe H, Hein J, Wolff KD, Mitchell DA, Kesting MR, et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid – a prospective study over 6 years. J Cranio-Maxillofac Surg. 2016;44(10):1689–93.
doi: 10.1016/j.jcms.2016.07.026
Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20(1):117–20.
pubmed: 18689864
doi: 10.1093/annonc/mdn554
Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma. 2008;49(11):2156–62.
pubmed: 19021059
doi: 10.1080/10428190802483778
Kwon YD, Kim DY, Ohe JY, Yoo JY, Walter C. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(12):2644–8.
pubmed: 19925985
doi: 10.1016/j.joms.2009.04.067
Ottesen C, Schiodt M, Jensen SS, Kofod T, Gotfredsen K. Tooth extractions in patients with cancer receiving high-dose antiresorptive medication: a randomized clinical feasibility trial of drug holiday versus drug continuation. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022;133(2):165–73.
pubmed: 34275774
doi: 10.1016/j.oooo.2021.06.003
Hoefert S, Yuan A, Munz A, Grimm M, Elayouti A, Reinert S. Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ). J Craniomaxillofac Surg. 2017;45(4):570–8.
pubmed: 28238559
doi: 10.1016/j.jcms.2017.01.013
Watters AL, Hansen HJ, Williams T, Chou JF, Riedel E, Halpern J, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(2):192–200.
pubmed: 23036797
doi: 10.1016/j.oooo.2012.05.017
Liu C, Wang L, Liu L, Zhuang J, Tang S, Zhang T, et al. Efficacy and safety of de-escalation bone- modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis. Cancer Manag Res. 2018;21(10):3809–23.
doi: 10.2147/CMAR.S176811
ESMO. De-escalation of commonly used bone-treating agents is a reasonable treatment option for patients with bone metastases from breast cancer. https://www.esmo.org/oncology-news/de-escalation-of-commonly-used-bone-treating-agents-is-a-reasonable-treatment-option-for-patients-with-bone-metastases-from-breast-cancer .
Yao S, Ding X, Rong G, Zhou J, Zhang B. Association between malignant diseases and Medication-Related Osteonecrosis of the Jaw (MRONJ): a systematic review and meta-analysis. J Craniofac Surg. 2023;34(2):669-73.
doi: 10.1097/SCS.0000000000009033
pubmed: 37646567
pmcid: 10292568
Gross J, Méder ZZ, De Dreu CKW, Romano A, Molenmaker WE, Hoenig LC. The evolution of universal cooperation. Sci Adv. 2023;9(7):eadd8289.
pubmed: 36800427
pmcid: 9937576
doi: 10.1126/sciadv.add8289
Zajac S, Woods A, Tannenbaum S, Salas E, Holladay CL. Overcoming challenges to teamwork in healthcare: a team effectiveness framework and evidence-based guidance. Front Commun. 2021. https://doi.org/10.3389/fcomm.2021.606445 .
doi: 10.3389/fcomm.2021.606445
Weller J, Boyd M, Cumin D. Teams, tribes and patient safety: overcoming barriers to effective teamwork in healthcare. Postgrad Med J. 2014;90(1061):149–54.
pubmed: 24398594
doi: 10.1136/postgradmedj-2012-131168
Emanuele J, Koetter L. Workflow Opportunities and Challenges in Healthcare. 2007 BPM & Workflow Handbook. 2007;1(1):157.
Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1–34)]. J Oral Maxillofac Surg. 2007;65(3):573–80.
pubmed: 17307613
doi: 10.1016/j.joms.2006.10.076
Drudge-Coates L, Van den Wyngaert T, Schiødt M, van Muilekom HAM, Demonty G, Otto S. Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals. Support Care Cancer. 2020;28(9):4019–29.
pubmed: 32307659
pmcid: 7378104
doi: 10.1007/s00520-020-05440-x